|August 12, 2013|
|18:14 EDT||AMGN||Amgen, Servier complete product collaboration deal|
Amgen and Servier announced the early termination of the waiting period under the Hart–Scott–Rodino Antitrust Improvements Act of 1976 in connection with the cardiovascular product collaboration agreement announced on July 8, completing the transaction. Under the terms of the agreement, Amgen has obtained commercial rights in the U.S. to Servier's novel oral drug, approved in the EU as Procoralan, for chronic heart failure and stable angina in patients with elevated heart rates. Amgen has also received an exclusive option to develop and commercialize Servier's investigational molecule, S38844, for cardiovascular diseases in the U.S. Currently, S38844 is in Phase 2 studies for the treatment of heart failure. Through the collaboration, Servier has obtained an exclusive option to commercialize omecamtiv mecarbil in Europe.
News For AMGN From The Last 14 Days
Check below for free stories on AMGN the last two weeks.
|December 10, 2013|
|07:41 EDT||AMGN||Oppenheimer to hold a conference|
24th Annual Healthcare Conference is being held in New York on December 10-11.
|December 6, 2013|
|08:31 EDT||AMGN||Amgen unit, International Myeloma Foundation announce partnership|
The International Myeloma Foundation and Onyx Pharmaceuticals, an Amgen subsidiary, announced the start of a multi-year collaboration in support of the IMF's Black Swan Research Initiative. The BSRI is led by a multinational consortium of leading myeloma experts who are studying and harnessing new technologies and treatments with the goal of developing a cure for myeloma.
|06:19 EDT||AMGN||Amgen price target lowered to $131 from $139 at Citigroup|
Citigroup lowered its price target for Amgen shares to $131 after dropping its estimates for the company's myeloma drug Kyprolis to below consensus. Citi believes the drug's inconvenience and cardiac toxicities are limiting its uptake and while drugs in late stage development offer far more appealing profiles. Citi, however, keeps a Buy rating on Amgen.
|December 3, 2013|
|09:37 EDT||AMGN||Active equity options trading on open|
Active equity options trading on open according to Track Data: CELG YHOO BX ARIA GS NXPI DG AMGN SLW MRK
|December 2, 2013|
|14:03 EDT||AMGN||Amgen pegfilgrastim granted orphan status for treatment of myelosuppression|
|November 27, 2013|
|13:05 EDT||AMGN||Amgen Neupogen granted orphan designation by FDA|
The drug received orphan designation for treatment of subjects at risk of developing myelosuppression after a radiological or nuclear incident. Reference Link
|November 26, 2013|
|16:14 EDT||AMGN||Amgen coverage resumed with an Overweight at Piper Jaffray|